📊 ROIV Key Takeaways
Is ROIV a Good Investment? Thesis Analysis
Roivant Sciences is a pre-revenue stage pharmaceutical company with minimal revenue ($5.7M) and massive operating losses (-$930.3M), burning cash at an unsustainable rate of -$593.5M annually in free cash flow. While the company maintains a strong balance sheet with $1.5B in cash and low debt (0.07x D/E), this provides only ~2.5 years of runway at current burn rates with no visible path to profitability or commercial viability.
Why Buy ROIV? Key Strengths
- Strong liquidity position with $1.5B in cash and 30.66x current ratio
- Conservative capital structure with minimal debt (Debt/Equity 0.07x) and low financial risk
- Solid equity base of $4.3B providing balance sheet cushion for continued operations
ROIV Investment Risks to Consider
- Unsustainable cash burn of -$593.5M annually will deplete cash reserves within 2-3 years without material revenue growth
- Revenue base of only $5.7M with -11.2% YoY decline indicates failed commercialization efforts or non-viable product portfolio
- Massive operating losses (-$930.3M) and negative operating margin of -16,207.5% demonstrate fundamental operational failure to generate revenue from cost structure
- No evidence of near-term catalysts for profitability or successful drug development in provided data
Key Metrics to Watch
- Revenue growth rate and pipeline advancement toward FDA approvals
- Quarterly cash burn rate and months of cash runway remaining
- Operating expense reduction initiatives and path to operating break-even
ROIV Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 30.66x current ratio provides a solid financial cushion.
ROIV Profitability Ratios
ROIV vs Healthcare Sector
How Roivant Sciences Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ROIV Overvalued or Undervalued?
Based on fundamental analysis, Roivant Sciences Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ROIV Balance Sheet & Liquidity
ROIV 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Roivant Sciences Ltd.'s revenue has declined by 41% over the 5-year period, indicating business contraction. The most recent EPS of $-1.42 indicates the company is currently unprofitable.
ROIV Growth Metrics (YoY)
ROIV Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.0M | $34.5M | $0.05 |
| Q2 2025 | $1.6M | -$113.5M | $-0.17 |
| Q1 2025 | $2.2M | $95.3M | $0.12 |
| Q3 2024 | $9.0M | $34.5M | $0.05 |
| Q2 2024 | $3.6M | -$134.9M | $-0.18 |
| Q1 2024 | $21.6M | $95.3M | $0.12 |
| Q3 2023 | $17.1M | -$352.0M | $-0.49 |
| Q2 2023 | $12.5M | -$291.6M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ROIV Capital Allocation
ROIV SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Roivant Sciences Ltd. (CIK: 0001635088)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ROIV
What is the AI rating for ROIV?
Roivant Sciences Ltd. (ROIV) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ROIV's key strengths?
Claude: Strong liquidity position with $1.5B in cash and 30.66x current ratio. Conservative capital structure with minimal debt (Debt/Equity 0.07x) and low financial risk.
What are the risks of investing in ROIV?
Claude: Unsustainable cash burn of -$593.5M annually will deplete cash reserves within 2-3 years without material revenue growth. Revenue base of only $5.7M with -11.2% YoY decline indicates failed commercialization efforts or non-viable product portfolio.
What is ROIV's revenue and growth?
Roivant Sciences Ltd. reported revenue of $5.7M.
Does ROIV pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
Where can I find ROIV SEC filings?
Official SEC filings for Roivant Sciences Ltd. (CIK: 0001635088) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ROIV's EPS?
Roivant Sciences Ltd. has a diluted EPS of $-0.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ROIV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Roivant Sciences Ltd. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ROIV stock overvalued or undervalued?
Valuation metrics for ROIV: ROE of -14.1% (sector avg: 15%), net margin of -10,501.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ROIV stock in 2026?
Our dual AI analysis gives Roivant Sciences Ltd. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ROIV's free cash flow?
Roivant Sciences Ltd.'s operating cash flow is $-586.5M, with capital expenditures of $6.9M. FCF margin is -10,339.4%.
How does ROIV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,501.1% (avg: 12%), ROE -14.1% (avg: 15%), current ratio 30.66 (avg: 2).